Trial Profile

Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 21 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eprenetapopt (Primary) ; Pembrolizumab (Primary)
Indications Bladder cancer; Carcinoma; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Urogenital cancer
Focus Adverse reactions
Sponsors Aprea Therapeutics

Most Recent Events

01 Jun 2022 Status changed from active, no longer recruiting to completed.
18 Jan 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Apr 2022.
18 Jan 2022 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com